Similar transplantation outcomes in patients bridged with cardiac assist devices for acute cardiogenic shock versus chronic heart failure

Utah Transplantation Affiliated Hospitals (U.T.A.H.) Cardiac Transplant Program, LDS Hospital, and University of Utah School of Medicine, Salt Lake City, Utah 84143, United States.
European Journal of Heart Failure (Impact Factor: 6.53). 09/2007; 9(8):845-9. DOI: 10.1016/j.ejheart.2007.05.002
Source: PubMed


Heart failure (HF) patients may require cardiac assist device implantation prior to transplantation (Tx) because of either acute cardiogenic shock (ACS), with no prior history of HF, or for progression of pump failure in the setting of chronic HF.
To investigate whether patients implanted with a cardiac assist device for ACS, have similar post-Tx outcomes as those who underwent cardiac assist device implantation because of progressive chronic HF.
We compared post-Tx outcomes of consecutive patients bridged due to ACS (Acute Group) with the outcomes of patients bridged due to deterioration of chronic HF (Chronic Group). Seventy-three patients had a cardiac assist device implanted and underwent subsequent cardiac Tx. Thirty-five patients (48%) had a cardiac assist device implanted due to ACS, most often caused by massive acute myocardial infarction, and 38 patients (52%) because of progressive chronic HF. Despite greater compromise at the time of implantation, the Acute Group recovered satisfactorily and underwent Tx with similar post-Tx survival rates as the Chronic Group patients [1-year survival: 88.6% vs 86.8%, p=0.80, actuarial survival (mean follow-up 4.2 years): 80.0% vs 81.6%, p=0.86)]. Furthermore, no significant differences were observed between the 2 groups in various post-Tx events.
Patients with ACS who underwent emergency cardiac assist device implantation as bridge to Tx had similar post-Tx outcomes as their more chronically ill counterparts who underwent device implantation on a non-urgent basis.

Download full-text


Available from: Benjamin D Horne, Oct 02, 2015
7 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Acute cardiogenic shock has a high mortality. The number of mechanical circulatory assist devices to encounter this life-threatening condition is steadily growing. These devices enable physicians to treat patients with acute cardiac failure refractory to conventional therapy. Mechanical circulatory assist devices are considered last resort to prevent or to reverse a cardiogenic shock. Different centrifugal, pulsatile or nonpulsatile (axial) flow pumps are available to rescue patients in different scenarios. These mechanical circulatory assist devices can be placed percutaneously or surgically as extracorporeal or intracorporeal mechanical circulatory assist devices. Percutaneous mechanical circulatory assist devices are useful to establish rapid life-saving circulatory support under different circumstances. A stabilized patient can then be transferred to an intensive care unit, a catheterization laboratory or an operating room for further assessment and additional treatment with possible change to a mid-term or long-term mechanical circulatory assist device. Percutaneous mechanical circulatory assist devices can be implanted in an emergency setting in patients with acute cardiogenic shock refractory to conventional therapy irrespective of the given location. The choice for a specific mechanical circulatory assist device should be based on the underlying condition and individualized prognosis. Based on the findings of this review, circulatory or axial-flow pumps should be considered first-line devices.
    Current opinion in cardiology 07/2008; 23(4):399-406. DOI:10.1097/HCO.0b013e328303e134 · 2.70 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The mortality of acute heart failure (AHF) remains high despite advances in treatment. Mechanical circulatory support (MCS) can be applied in AHF, refractory to conventional measures, to improve outcomes. This article aims to describe the current and the prospective role of MCS in the treatment of AHF. The support strategies and the indications of MCS are continuously evolving, including situations considered as contraindications in the past. Appropriate patient selection, advanced device technology and improved patient management have contributed to the substantially improved results. Evolution in device technology results in evolution of the clinical applications of MCS. Earlier application of MCS, with novel, flexible and individualized support strategies is now feasible. Bridging to recovery is the most intriguing support strategy and bridging to future treatments is feasible with long-term support. The progressively expanding role of MCS in the treatment of heart failure is not reflected in the existing guidelines. Being reserved for refractory heart failure, MCS has been applied to the sickest patients who were less amenable to randomization. This explains the lack of robust evidence, but also highlights the value of the progressively improving results. The anticipated wider application of MCS should be better defined, systematically recorded, and guided.
    Acute Cardiac Care 10/2009; 11(4):204-15. DOI:10.1080/17482940903177028
  • [Show abstract] [Hide abstract]
    ABSTRACT: Extracorporeal membrane oxygenation (ECMO) systems have undergone rapid technological improvements and are now feasible options for medium-term support of severe cardiac or pulmonary failure. Intractable ventricular arrhythmia is a rare but well-established indication for heart transplantation. We report a case of persistent ventricular fibrillation (VF) that was rescued by insertion of peripheral veno-arterial ECMO during cardiopulmonary resuscitation, which provided support for 30 h of continuous VF and subsequently permitted urgent heart transplantation.
    European Journal of Heart Failure 03/2010; 12(3):301-4. DOI:10.1093/eurjhf/hfq012 · 6.53 Impact Factor
Show more